3SOF

Candlestick mumbo jumbo.....
genz has formed a star. prices should go higher.

http://stockcharts.com/def/servlet/SC.web?c=genz


Genzyme beats by $0.05; guides Q1 below consensus, Y05 in line (GENZ) Reports Q4 (Dec) earnings of $0.52 per share, ex items, $0.05 better than the Reuters Estimates consensus of $0.47; revenues rose 24.1% year/year to $591.1 mln vs the $586.7 mln consensus. Company expects Q1 (Mar) EPS of $0.45-0.48 (Reuters consensus $0.49); for Y05 co sees EPS of $2.08-2.16, on revs of $2.5-2.7 bln (vs $2.10, $2.5 bln).

I'm sorry setravis but this last candle on GENZ doesn't mean, at all, the stock is going higher. You could have a star in the south or something like that signaling reversal of a bearish trend, but this candle in not at a low point ...

This doesn't mean the stock won't go higher, but that candlestick analysis has too much mumbo jumbo 

Would you like me to recommend you a good book on candles? I really love the candlestick theory too ... it is the Candlestick Charting Explained, from Gregory L. Morris.

Have a nice day, let me leave the GENZ chart here:

David
This was based on candlestick frequency "One WEEK", NOT DAILY!
Take a look at a weekly chart. I could not post the chart due to tech problems.
Thank you David I have read , as I don't think there is a book out on candlesticks
that I have not read. Good trading

This is a welcome ........

Genzyme ((GENZ.O)) Q2 earnings rise




CHICAGO, July 14 (Reuters) - Genzyme Corp. (GENZ,Trade) on Thursday said second-quarter profit rose 58 percent, beating analysts' expectations, helped by sales of its drugs to treat rare and chronic diseases and improved margins.

The Cambridge, Massachusetts-based biotechnology company raised its full-year revenue and earnings outlook.

For the second quarter, Genzyme posted a net profit of $123.6 million, or 46 cents per share, up from $78.2 million, or 33 cents a share, a year earlier.

Excluding one-time items, Genzyme earned 57 cents per share. Analysts' average estimate was 53 cents, according to Reuters Estimates.

Revenue increased 22 percent to $668.1 million from $549.6 million in the same quarter last year.

For the full year, Genzyme raised its revenue estimate to a range of $2.6 billion to $2.8 billion, up from a prior range of $2.5 billion $2.7 billion.

It raised its net earnings forecast to a range of $1.75 to $1.80 per share, up from a previous range of $1.72 to $1.78.

Excluding amortization and in-process research and development costs of 45 cents per share, it expects earnings of $2.20 to $2.25 per share, up from an earlier view of $2.12 to $2.18.

For the third quarter, Genzyme expects net earnings of 45 to 47 cents per share. Excluding amortization and in-process research and development costs of 10 cents per share, it expects earnings of 55 cents to 57 cents per share.

News Link:

http://finance.yahoo.com/q/h?s=GENZ

A nice move. Volume and price action.

Genzyme climbs on drug news
at MarketWatch (Thu 4:59pm


Genzyme Corporation Conference Call to discuss Positive Results from DCOR Trial Favoring Use of Renagel Thu, Jul 28, 2005, 10:00 am Eastern

[$$] Genzyme's Renagel Could Cut Dialysis Patients' Risks of Death
at The Wall Street Journal Online (Thu 5:13p

Had a pull back.
Looks ready to make a run to the upside.
Stochastic coming out of oversold area and has turned north.
Support @ $67.61......Resistance @ $70.04


Technicals
Stochastic - Bullish

Last Price Quote is:
-0.77%below 13-day EMA
3.32%above 50-day EMA
RS Rating: 70 

Fundamentals
Key Data:
Market Cap (M): $18,067.24 
P/E Ratio: 127.96 
PEG Ratio: 1.60622 
Next Earnings: 10/19/2005
Last Analyst Rating: Equal-weight

Symmetrical Triangle (continuation) Pattern, Breakout.
Earnings up for the last 4 quarters.

• Genzyme upgraded by Bear Stearns
Briefing.com (Wed 7:33am) 

Support @ $73.48...72.15...71.06
Resistance @ $75.20
MACD is Bullish
Stochastic is neutral

Technicals
Last Price Quote is:
3.25%above 13-day EMA
5.44%above 50-day EMA
RS Rating: 78 

Fundamentals
Analyst Upgrade to Outperform
Coverage Initiated: Outperform

Key Data:
Market Cap (M): $19,204.30 
P/E Ratio: 132.28 
PEG Ratio: 1.66146 
Next Earnings: 02/16/2006
Last Analyst Rating: Outperform

Symmetrical Triangle (Continuation)
The symmetrical triangle, which can also be referred to as a coil, usually forms during a trend as a continuation pattern. The pattern contains at least two lower highs and two higher lows. When these points are connected, the lines converge as they are extended and the symmetrical triangle takes shape. You could also think of it as a contracting wedge, wide at the beginning and narrowing over time.

While there are instances when symmetrical triangles mark important trend reversals, they more often mark a continuation of the current trend. Regardless of the nature of the pattern, continuation or reversal, the direction of the next major move can only be determined after a valid breakout.

Edwards and Magee suggest that roughly 75% of symmetrical triangles are continuation patterns and the rest mark reversals. The reversal patterns can be especially difficult to analyze and often have false breakouts. Even so, we should not anticipate the direction of the breakout, but rather wait for it to happen. Further analysis should be applied to the breakout by looking for gaps, accelerated price movements, and volume for confirmation. Confirmation is especially important for upside breakouts.

Prices sometimes return to the breakout point of apex on a reaction move before resuming in the direction of the breakout. This return can offer a second chance to participate with a better reward to risk ratio. Potential reward price targets found by measurement and parallel trend line extension are only meant to act as rough guidelines. Technical analysis is dynamic and ongoing assessment is required.

• InPlay: Genzyme staging a breakout above 76.06/76.17 to a new high
Briefing.com (Fri 9:50am) 


Market Scan
Genzyme's Renagel Seen With Long-Term Effectiveness
Peter Kang, 11.11.05, 4:12 PM ET


Credit Suisse First Boston maintained an "outperform" rating on Genzyme (nasdaq: GENZ - news - people ) after the biotech firm released trial data for high-priced kidney drug Renagel.

Results from the study known as DCOR indicated Renagel patients experienced a 9% reduced risk of death, compared with those using calcium-based phosphate binders.

Analyst Mark Augustine said the data, recently presented at the annual meeting of the American Society of Nephrology, came in consistent with expectations. Genzyme released preliminary results in late July.

The analyst said the significance of the three-year trial, which monitored 2,100 patients, is that it demonstrated the drug's long-term effectiveness, particularly for those over the age of 65. Serious adverse events were minimal and not remarkable, Augustine noted.

"We expect the impact of DCOR data and Medicare Part D to be favorable to Renagel, although in a gradual sense," Augustine wrote, in a note to clients. "Prescription trends over the next three or so months bear watching."

The research analyst reiterated a price target of $80 and highlighted Genzyme's significant leverage on the kidney drug, estimating that $100 million in sales represents an additional 20 cents per share in earnings.

updated chart look...
Possible Double Bottom (Reversal) Pattern